<a href="https://laohu8.com/S/JBIO">Jade Biosciences</a> Announces $135 Million Private Placement to Fund Autoimmune Disease Therapies
Jade Biosciences Inc. (Nasdaq: JBIO), a clinical-stage biotechnology company focused on therapies for autoimmune diseases, has announced a private placement expected to raise approximately $135 million in gross proceeds. The financing saw participation from both new and existing investors, including Janus Henderson Investors, RA Capital Management, Marshall Wace, and others. Under the terms of the agreement, Jade Biosciences is selling 13,368,164 shares of common stock at $9.14 per share and pre-funded warrants to purchase 1,402,092 shares at $9.1399 per warrant. The pre-funded warrants have an exercise price of $0.0001 per share and can be exercised at any time, subject to certain ownership limitations. Following the transaction, Jade will have about 67.4 million shares and equivalents outstanding. Jefferies, TD Cowen, Stifel, and Wedbush & Co. are acting as placement agents for the transaction. The company plans to use the net proceeds to support research and development, general corporate purposes, and working capital, with current cash resources expected to fund operations into the first half of 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541229-en) on October 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.